

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 24, 2025

OPM-2

RRID:CVCL_1625

Type: Cell Line

Proper Citation

(RRID:CVCL_1625)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1625

Proper Citation: (RRID:CVCL_1625)

Sex: Female

Defining Citation: [PMID:3926660](#), [PMID:8943038](#), [PMID:10087940](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:20164919](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Characteristics: Produces Ig lambda., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: OPM-2

Synonyms: OPM2

Cross References: BTO:BTO_0005919, CLO:CLO_0008269, EFO:EFO_0006716,

CLDB:cl3774, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, BioGRID_ORCS_Cell_line:977, BioSample:SAMN03473240, BioSample:SAMN10988562, cancercellines:CVCL_1625, Cell_Model_Passport:SIDM00457, CGH-DB:36-1, CGH-DB:9158-4, ChEMBL-Cells:ChEMBL3308883, ChEMBL-Targets:ChEMBL2366353, Cosmic:720767, Cosmic:735529, Cosmic:759901, Cosmic:759907, Cosmic:760390, Cosmic:760403, Cosmic:909249, Cosmic:1889515, Cosmic:2081432, Cosmic:2302417, Cosmic:2367300, Cosmic:2391792, Cosmic:2809760, Cosmic-CLP:909249, DepMap:ACH-000024, DSMZ:ACC-50, DSMZCellDive:ACC-50, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909249, GEO:GSM143336, GEO:GSM290303, GEO:GSM562818, GEO:GSM887478, GEO:GSM888559, GEO:GSM1374799, GEO:GSM1670307, IARC_TP53:21603, IARC_TP53:28518, LiGeA:CCELE_834, LINCS_LDP:LCL-2048, PharmacnoDB:OPM2_1202_2019, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_1625, PubChem_Cell_line:CVCL_1625, Wikidata:Q54936482

ID: CVCL_1625

Record Creation Time: 20250131T202155+0000

Record Last Update: 20250131T204011+0000

Ratings and Alerts

No rating or validation information has been found for OPM-2.

No alerts have been found for OPM-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ticona-Pérez FV, et al. (2024) Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. Cancer cell international, 24(1), 275.

Pu J, et al. (2024) Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. Clinical & translational immunology, 13(3), e1500.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. *Research square*.

Costacurta M, et al. (2024) Mapping the IMiD-dependent cereblon interactome using BioID-proximity labelling. *The FEBS journal*.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Aubry A, et al. (2023) Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses. *Cell reports*, 42(8), 112925.

Beltrán-Visiedo M, et al. (2023) Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. *Molecular oncology*, 17(12), 2507.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. *iScience*, 25(3), 103985.

Sabol HM, et al. (2022) Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. *Neoplasia (New York, N.Y.)*, 28, 100785.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. *Cell reports*, 34(1), 108532.

Vervoort SJ, et al. (2021) The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. *Cell*, 184(12), 3143.

Lo CH, et al. (2021) Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. *Cancer research*, 81(9), 2415.

Fucci C, et al. (2020) The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis. *Cell reports*, 32(12), 108162.

Low MSY, et al. (2019) IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis. *Cell reports*, 29(9), 2634.

Shemorry A, et al. (2019) Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. *eLife*, 8.

Steinberger J, et al. (2019) Tracing MYC Expression for Small Molecule Discovery. *Cell chemical biology*, 26(5), 699.

Lu G, et al. (2018) UBE2G1 governs the destruction of cereblon neomorphic substrates. *eLife*, 7.